Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zotarolimus - AbbVie

Drug Profile

Zotarolimus - AbbVie

Alternative Names: ABT 578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm); Resolute Onyx; ZoMaxx; Zotarolimus-eluting coronary stent system

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Medtronic
  • Class Ischaemic heart disorder therapies; Lactones; Macrolides; Polyenes; Tetrazoles
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Erectile dysfunction
  • Discontinued Vascular restenosis

Most Recent Events

  • 26 Sep 2019 Efficacy data from a Onyx ONE trial in patients with Coronary artery restenosis (High-bleeding risk patients) released by Medtronic
  • 21 Feb 2019 Medtronic completes a clinical trial in Coronary artery restenosis in USA (NCT02412501)
  • 03 Dec 2018 Medtronic completes a phase II trial for Coronary artery restenosis in USA (NCT02419521)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top